Grants, prizes, business angels, health VCs: which funding sources exist at each stage of a Swiss medtech, and how CE marking, clinical studies and LAMal reimbursement shape your round. Real 2026 examples.
The short answer
A Swiss medtech start-up is rarely funded in a single round. The typical path stacks three layers:
- Non-dilutive money to prove it works: Venture Kick, BRIDGE, Innosuisse, cantonal programmes and prizes. Plan on a few hundred thousand francs, without giving up any capital.
- A seed round to reach CE marking: business angels (often doctors), then a first specialised VC. This is the hardest round, because the product cannot be sold yet.
- A growth round once reimbursement is in sight: health VCs, family offices and players in the healthcare system.
What sets medtech apart from other sectors is that regulatory milestones replace commercial milestones. An investor will not ask for your revenue. They will ask where you stand on your device class, your notified body and your reimbursement strategy. This guide follows that path step by step.
-
Prove the technology
Milestone to reach: a working prototype and an incorporated company
Who pays: Venture Kick, BRIDGE, university fellowships, cantonal programmes, prizes
Median CHF 100 k across 16 rounds in our database (half between CHF 50 k and CHF 292 k)
-
Prototype and compliance
Milestone to reach: a quality system, a chosen notified body, technical documentation under way
Who pays: Innosuisse, health accelerators, cantonal loans
Median CHF 100 k across 13 rounds in our database (half between CHF 100 k and CHF 250 k)
-
Seed up to CE
Milestone to reach: CE marking and the first installations
Who pays: physician business angels, angel networks, first specialised VCs
Median CHF 2 M across 14 rounds in our database (half between CHF 1.4 M and CHF 4.1 M)
-
Growth
Milestone to reach: a reimbursement route and rising sales
Who pays: health VCs, family offices, corporates, healthcare system players
Median CHF 15.2 M across 9 rounds in our database (half between CHF 12 M and CHF 40 M)
Why medtech is funded differently
In software, you can sell an imperfect first version and raise on traction. In a medical device, you are not allowed to sell before you are compliant. Three consequences for your funding plan:
- The time before the first franc of revenue is long. Between prototype and market launch you need a quality management system, technical documentation, often clinical data, and an assessment by a notified body for most device classes.
- The risk is regulatory first. A certification delay costs more than a development delay, because the whole team waits. Investors know this, and they value highly the teams that already have regulatory expertise on board.
- Being certified is not enough to sell. Someone still has to pay: the hospital, the patient or the health insurer. This reimbursement question comes up in due diligence much earlier than most founders expect.
Investors in the sector are blunt about it. In our directory, VI Partners lists among its warning signs “a team with no regulatory profile for medtech”. Hiring or bringing in that profile early is often the best investment before a round.
These constraints show in the numbers: medtechs rely on non-dilutive money far more than the average Swiss startup.
How health & medtech gets funded
42% of the health & medtech rounds we track are non-dilutive (grants, loans, prizes), against 35% for all Swiss startups. 28% are equity rounds, against 32%.
Grants, loans and prizesEquityType or amount not stated
Rounds per month, last twelve months
Step 1: prove the technology without giving up capital
At this stage you have a technology, often spun out of a university, and a first prototype. The goal is to fund the proof of concept and set up the company without diluting too early.
| Source | What it funds | Indicative amount |
|---|---|---|
| Venture Kick | The first steps of the company, in three stages before a jury | Up to CHF 150,000 |
| BRIDGE (SNSF and Innosuisse) | The move from research to application, for researchers | Up to CHF 500,000 depending on the track |
| University fellowships | Innogrant (EPFL), Pioneer Fellowship (ETH Zurich) and equivalents | A founder’s salary for 12 to 18 months |
| Cantonal programmes | Depending on your canton: FIT in Vaud, FIF in Geneva, and others | Grants and loans of around CHF 100,000 |
| Sector prizes | Swiss Medtech Award, innovation park prizes, competitions | CHF 10,000 to CHF 50,000 |
Two recent examples from our database:
- CHD (Connected Health Development), based on the Biopôle campus, develops a connected textile belt to monitor high-risk pregnancies. In October 2026 it received CHF 150,000 from Venture Kick to fund its working prototypes, as the first tranche of its seed round.
- dEEGtal, at the Wyss Center on the Campus Biotech in Geneva, uses artificial intelligence to analyse electroencephalograms for diagnosing epilepsy. The CHF 100,000 from the FIF Geneva funds its regulatory work and its entry into the US market.
What these funds share is that they are tied to one specific milestone (a prototype, a regulatory file), and that milestone is what makes the next round possible. For the full list of programmes in your canton, see grants by canton (in French).
Step 2: fund the prototype and prepare compliance
Once the company exists, two non-dilutive levers are often underused by medtechs.
Innosuisse innovation projects for start-ups. Innosuisse can fund a young company directly, without a research partner, for up to 70% of the direct costs of an innovation project. The published conditions target Swiss start-ups that are under five years old, have fewer than 50 full-time equivalents, and do not yet have a product ready for series production. For a medtech, this is often the way to fund the device development that comes before certification. Check the current conditions on the Innosuisse website before you apply.
Health accelerators. In Basel, DayOne runs a three-month programme with CHF 50,000 in subsidy and CHF 50,000 in services, with direct access to the pharma network. On the Lake Geneva arc, the Biopôle and Campus Biotech parks play a similar role as an address and a network.
This is also the moment to choose your notified body and build your quality system (ISO 13485 in most cases). These two decisions set the timeline for everything that follows, and seed investors will ask about them.
Step 3: the seed round, up to CE marking
This is the round that hurts medtech founders the most. It must fund certification, often a clinical study, and the first installations, while the product cannot yet be sold.
A real trajectory
Prevision Medicine
Ten months between a non-dilutive incubation programme and a seed round: Prevision Medicine shows how a modest first grant prepares the round that pays for approval.
-
Grantwith Biopôle SA
The company has joined the Biopôle Investment Programme, which offers non-dilutive funding of up to CHF 90,000.
See the round -
SeedUSD 5.4 Mwith ACE Ventures, GoHub Ventures, SICTIC
The Zurich-based company has closed a USD 5.4 million seed round, led by ACE Ventures, to obtain approvals and reimbursement and expand in Europe.
See the round
The takeaway: the seed round is not pitched as a growth round but as the way to secure approvals and reimbursement. That is exactly what medtech investors want to read in the use of funds.
How much and for what
For a class IIa or higher device, CE marking typically represents several hundred thousand francs and 12 to 24 months of work, not counting a possible clinical study. These are orders of magnitude: ask your notified body for an estimate before you fix the size of your round, and build in a margin, because review timelines often stretch.
The amount to raise is therefore the one that takes you to the certificate and a few months beyond it, so you have time to sign your first customers before the next round.
Who invests at this stage
- Doctors and surgeons as business angels. This is a strong feature of medtech. They understand the clinical need, open their services for trials and reassure the investors who follow. avaisor, which captures how surgeons reason in the operating theatre, raised CHF 488,000 in pre-seed in November 2026 from more than fifteen surgeons, a Singapore family office and a Swiss business angel.
- Angel networks. Business Angels Léman lists health among its sectors, with tickets of CHF 25,000 to 250,000.
- First specialised VCs. VI Partners (EPFL and ETH spin-offs, tickets of CHF 0.5 to 5 million) and DART Ventures (health and climate, tickets of CHF 0.25 to 1.5 million) typically come in at this stage.
- Cantonal loans. They work well alongside an equity round. PolaSight, a University of Bern spin-off that maps tissue during cancer surgery, obtained a CHF 100,000 loan from the FIT to fund its CE marking and its first hospital installations.
The European option
Since 2025, Switzerland has been associated with Horizon Europe, and Swiss start-ups can apply to the EIC Accelerator: up to €2.5 million in grant funding, with an equity option. Selection is very competitive, but a medtech file with a strong clinical need and a clear regulatory roadmap has a place there.
What Swiss regulation changes in your plan
Selling in Switzerland and in the European Union
Switzerland has aligned its regulation (the Medical Devices Ordinance, ODim) with the European MDR regulation. However, the mutual recognition agreement with the EU has not been updated for medical devices. The practical consequences:
- To sell in the EU, a manufacturer based in Switzerland is treated as a manufacturer from a third country: it must appoint an authorised representative established in the EU.
- For the Swiss market, a foreign manufacturer must appoint a Swiss authorised representative, known as the CH-REP, registered with Swissmedic.
These representatives carry an annual cost. Include it in your financial plan from the seed round, and show your investors that you anticipated it.
The clinical study
A clinical investigation carried out in Switzerland must be authorised by the competent ethics committee and, depending on the type of device, by Swissmedic. It often costs more than the certification itself. Two ways to fund it: working with a university hospital (which can carry part of the costs in a research project), and an Innosuisse project built around the study.
Reimbursement by health insurance
Being certified does not guarantee being paid. In Switzerland, the reimbursement route depends on how your device is used:
| How the device is used | LAMal reimbursement route |
|---|---|
| By the patient, at home | The list of means and devices (MiGeL), managed by the FOPH |
| During an outpatient medical act | The outpatient medical tariff, TARDOC and outpatient flat rates, in force since 1 January 2026 (FOPH) |
| During an inpatient stay | SwissDRG hospital flat rates, paid to the hospital |
In the last two cases, it is not your device that is reimbursed but the act or the stay: the hospital or the doctor must have an economic interest in using it. Investors will ask you who pays, how much, and from when. One page of your pitch deck should answer this, even at seed stage.
Some medtechs get around this difficulty by starting in a market where the payer is simpler: the patient directly, a private clinic, or the United States, as dEEGtal did.
Step 4: growth, once the market is open
Once the certificate is obtained and the first customers have signed, the round changes in nature. You are no longer selling a technical promise, but an adoption curve and a reimbursement strategy.
- Health family offices. In Basel, 4FO Ventures, linked to the family that founded Roche, invests CHF 2 to 15 million in Series A and B, with a deep scientific due diligence of 8 to 16 weeks. Forestay Capital also covers health.
- Players in the healthcare system. Hospital groups and insurers are starting to invest in the solutions they will use. JIVITA, which integrates complementary medicine into partner clinics, brought Hirslanden into its capital in October 2026, after the health insurer EGK. A strategic investor of this kind brings revenue on top of capital, but check that it does not close the door on your competitors.
- Industrial players in the sector, who invest or acquire to complete their range. Exit by acquisition is the most common route in medtech: keep it in mind from the first round, because it guides the choice of your investors.
How varied the money becomes at this stage shows in Distalmotion’s year:
A real trajectory
Distalmotion
Once the product is on the market, the same company combines three kinds of money in less than a year: a large equity round, a corporate investor, then debt.
-
Series C and laterUSD 150 Mwith Revival Healthcare Capital
The USD 150 million Series G, with participation from existing investors, will mainly fund commercial expansion in the United States.
See the round -
Undisclosed roundwith Johnson & Johnson Innovation (JJDC)
Johnson & Johnson has made a strategic investment, amount undisclosed, to accelerate its rollout in these centres in the United States.
See the round -
Loanwith Perceptive Advisors
The company has entered into a secured term loan facility of up to USD 70 million with Perceptive Advisors to accelerate its growth in the United States.
See the round
The takeaway: at the growth stage, debt (here a secured term loan facility) complements equity, because recurring revenue makes it repayable. The corporate investor brings market access as much as money.
Five common mistakes
- Raising too little to reach the certificate. A round that runs out three months before CE marking forces you to raise again from the weakest position.
- Discovering the reimbursement question during due diligence. Prepare it before the first investor meeting.
- Ignoring non-dilutive funding after incorporation. Innosuisse, the EIC and cantonal loans remain open well after the academic phase.
- Choosing impatient investors. A generalist fund that expects revenue within 18 months will be a difficult partner. Ask each investor how many medical devices they have taken to market.
- Forgetting the recurring compliance costs. Authorised representatives, post-market surveillance and the notified body’s annual audits weigh on your cash well after certification.
Before you pitch, check that you can answer these questions
- What is your device’s class, and who confirmed it?
- Which notified body, what timeline, what budget for certification?
- Is a clinical study needed, and who will fund it?
- Who pays for your device, through which reimbursement route, and in which country first?
- Who on your team or your board has already put a medical device on the market?
If one answer is missing, it is probably what your next round must cover.
The sector in data
Updated with each Fundswiss watch: 88 deals tracked in health & medtech, each with its source.
Latest deals
- AVEALoan · CHF 1.3 M · 11 November 2026
- Dexterous EndoscopesGrant · Amount not disclosed · 9 November 2026
- CARELoan · CHF 2.3 M · 5 November 2026
- UNDAE ScienceSeed · CHF 1.2 M · 5 November 2026
- avaisorPre-seed · CHF 488,000 · 4 November 2026
Active investors in the sector
- VI PartnersVC · 0.5–5M
- DART VenturesVC · 0.25–1.5M
- Forestay CapitalFamily office · 1–10M
- 4FO VenturesFamily office · 2–15M
- DayOneAccelerator · CHF 100K
- Business Angels LémanBusiness angels · CHF 25–250K
- 3VCVC · Ticket sizes not disclosed; one recorded round of USD 10 M (Ahead Health)
- ACE VenturesVC · Ticket sizes not disclosed; recorded rounds of USD 3 M to USD 5.4 M
The whole health & medtech sector: investors, deals and upcoming dates